Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Plus Vorinostat for Relapsed or Refractory Lymphoma
NCT03150329Phase 1Active, not recruiting
- Sponsor
- City of Hope
- Start
- Sep 2017
- Primary completion
- Jun 2023
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of vorinostat and pembrolizumab in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and Hodgkin lymphoma (HL) (2 arms), sponsored by City of Hope. Primary endpoints: Number of Patients With Grade 3-5 Adverse Events up to 27 months, Maximum Tolerated Dose on Vorinostat and 1 more. Started Sep 2017; status: active, not recruiting.
02
Drugs
vorinostatpembrolizumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT03150329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03150329.